GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Quick Ratio

Medigen Biotechnology (ROCO:3176) Quick Ratio : 1.76 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Medigen Biotechnology's quick ratio for the quarter that ended in Mar. 2024 was 1.76.

Medigen Biotechnology has a quick ratio of 1.76. It generally indicates good short-term financial strength.

The historical rank and industry rank for Medigen Biotechnology's Quick Ratio or its related term are showing as below:

ROCO:3176' s Quick Ratio Range Over the Past 10 Years
Min: 1.22   Med: 2.5   Max: 7.58
Current: 1.76

During the past 13 years, Medigen Biotechnology's highest Quick Ratio was 7.58. The lowest was 1.22. And the median was 2.50.

ROCO:3176's Quick Ratio is ranked worse than
68.05% of 1543 companies
in the Biotechnology industry
Industry Median: 3.6 vs ROCO:3176: 1.76

Medigen Biotechnology Quick Ratio Historical Data

The historical data trend for Medigen Biotechnology's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Quick Ratio Chart

Medigen Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.26 2.89 3.91 5.74 1.86

Medigen Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.28 1.90 1.92 1.86 1.76

Competitive Comparison of Medigen Biotechnology's Quick Ratio

For the Biotechnology subindustry, Medigen Biotechnology's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Biotechnology's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Medigen Biotechnology's Quick Ratio falls into.



Medigen Biotechnology Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Medigen Biotechnology's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(5708.037-546.906)/2779.891
=1.86

Medigen Biotechnology's Quick Ratio for the quarter that ended in Mar. 2024 is calculated as

Quick Ratio (Q: Mar. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(5323.275-571.376)/2704.199
=1.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medigen Biotechnology  (ROCO:3176) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Medigen Biotechnology Quick Ratio Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigen Biotechnology (ROCO:3176) Business Description

Traded in Other Exchanges
N/A
Address
Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is a biopharmaceutical company primarily engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The new drug development business focuses mainly on the clinical stage of drug development and includes PI-88 MUPAFOSTAT for the treatment of liver cancer and OBP-301 treatment using adenovirus targeted to cancer cells only. Drug discovery includes the development of human-native mAbs for therapeutic applications related to infectious diseases. Generic drugs include pharmaceuticals for infectious diseases (antibiotics), contraceptives, nutrition milk powder, vitamin C tablets, dermatologic agents, and eye care products.

Medigen Biotechnology (ROCO:3176) Headlines

No Headlines